{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8"},{"groupId":"OG001","value":"65.8"}]}],"title":"Gram positive agents"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9"},{"groupId":"OG001","value":"35.5"}]}],"title":"Aminoglycosides"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1"},{"groupId":"OG001","value":"59.9"}]}],"title":"Third or fourth generation cephalosporins"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6"},{"groupId":"OG001","value":"85.7"}]}],"title":"Empiric antibiotics for fever and neutropenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"307"}],"units":"Participants"}],"description":"Exposure to antibiotics was considered during the infection observation period(s) was defined a priori as follows: Gram positive agents = vancomycin, linezolid, daptomycin or quinupristin/dalfopristin; Aminoglycosides = amikacin, gentamicin or tobramycin; Third or fourth generation cephalosporins = cefepime, ceftazidime, ceftriaxone or cefotaxime; Empiric antibiotics for fever and neutropenia = imipenem, meropenem, cefepime, ceftazidime or piperacillin/tazobactam","groups":[{"description":"Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.\n\nlevofloxacin: Given PO or IV","id":"OG000","title":"Arm I (Levofloxacin)"},{"description":"Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.","id":"OG001","title":"Arm II (Standard of Care)"}],"paramType":"NUMBER","populationDescription":"All evaluable, and centrally reviewed AL and HSCT patients are reported. Ineligible patients and patients who withdrew of consent prior to treatment were excluded.","reportingStatus":"POSTED","timeFrame":"Up to 60 days after enrollment or receiving levofloxacin","title":"Comparison of the Percentage of Patients Having Antibiotic Exposures Between Arms","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}